This site is intended for health professionals only
Wednesday 22 May 2019
Share |

Industry News

Six in 10 pharmacy professionals in favour of banning homeopathy prescribing

Friday 7th September 2018

Six in 10 pharmacy professionals are against the sale and dispensing of homeopathic products, pharmacists at an international conference have heard.
In a congress session taking place at the International Pharmaceutical Federation’s (FIP) World Congress of Pharmacy and Pharmaceutical Science on Tuesday (4 September), 63% of between 150 to 200 people surveyed said ‘...

Tue, 9 Jun 2015
Novo Nordisk announced that Xultophy® (insulin degludec/liraglutide; IDegLira), the first ever treatment combining two existing treatments, long acting (basal) insulin (insulin degludec, Tresiba®) (1) and GLP-1 receptor agonist (liraglutide, Victoza®) (2) in one pen, has been launched in the United Kingdom
Fri, 29 May 2015
Napp Pharmaceuticals Limited has announced that Targinact, a fixed combination of prolonged-release oxycodone/naloxone, has received approval for use in the UK. This follows the European Commission's positive decision in January 2015 to recommend Targinact as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy. (1,2)
Wed, 27 May 2015
Janssen-Cilag International NV (“Janssen”) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for the use of STELARA® (ustekinumab), for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
Tue, 26 May 2015
MSD, known as Merck & Co., Inc. in the United States and Canada, announced that SIMPONI® (golimumab) has received CHMP positive opinion for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). (1) Once the EU commission issues their EC decision, and if approved, nr-axial SpA patients can be considered for the once-monthly subcutaneous injection with SIMPONI® (golimumab).
Thu, 21 May 2015
Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase III study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Tue, 19 May 2015
Data presented from the CDI Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes. Compared to traditional broad-spectrum antibiotics, first-line use of fidaxomicin, a targeted treatment, in all CDI patients provides improved outcomes in terms of recurrence rate, all-cause mortality and cost effectiveness, compared to use in selected patients only. (8) CDI is associated with high-mortality (5,6,7) and cost burden, (9) therefore reducing the incidence and recurrence of CDI is a priority for clinicians, payers and health authorities alike.
Tue, 19 May 2015
Clinical experience of biosimilar infliximab in 78 inflammatory bowel disease (IBD) patients presented at Digestive Diseases Week (DDW) 2015 in Washington DC showed that the treatment is comparable to the reference medicinal product (RMP) in terms of efficacy and safety. Speaking at a satellite symposium hosted by Celltrion Healthcare, Jørgen Jahnsen, Professor of Gastroenterology at the University of Oslo, Norway, provided an update on his own clinical experience of treating patients with IBD in Norway with biosimilar infliximab, which represents the latest treatment development in IBD.

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher